| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| src Homology Domains | 19 | 2018 | 124 | 3.680 |
Why?
|
| Phosphopeptides | 14 | 2017 | 65 | 3.220 |
Why?
|
| STAT3 Transcription Factor | 17 | 2014 | 1121 | 2.880 |
Why?
|
| STAT6 Transcription Factor | 4 | 2018 | 67 | 1.440 |
Why?
|
| Prodrugs | 5 | 2015 | 217 | 1.190 |
Why?
|
| Molecular Mimicry | 8 | 2017 | 72 | 0.870 |
Why?
|
| Small Molecule Libraries | 2 | 2018 | 169 | 0.670 |
Why?
|
| Structure-Activity Relationship | 12 | 2018 | 931 | 0.670 |
Why?
|
| Silanes | 2 | 2009 | 6 | 0.660 |
Why?
|
| Peptides, Cyclic | 7 | 2005 | 139 | 0.650 |
Why?
|
| Glutamine | 3 | 2009 | 299 | 0.630 |
Why?
|
| Peptides | 12 | 2009 | 1479 | 0.630 |
Why?
|
| STAT5 Transcription Factor | 1 | 2018 | 214 | 0.590 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 10 | 1999 | 96 | 0.550 |
Why?
|
| Asthma | 4 | 2018 | 871 | 0.530 |
Why?
|
| Phosphotyrosine | 5 | 2012 | 111 | 0.520 |
Why?
|
| Iodides | 1 | 2014 | 14 | 0.510 |
Why?
|
| Alkalies | 1 | 2014 | 32 | 0.500 |
Why?
|
| Methylamines | 1 | 2014 | 21 | 0.500 |
Why?
|
| Oligopeptides | 5 | 2005 | 429 | 0.500 |
Why?
|
| GRB7 Adaptor Protein | 1 | 2014 | 4 | 0.490 |
Why?
|
| Models, Molecular | 6 | 2015 | 1732 | 0.480 |
Why?
|
| GRB2 Adaptor Protein | 1 | 2014 | 52 | 0.470 |
Why?
|
| Models, Chemical | 3 | 2011 | 186 | 0.420 |
Why?
|
| Biomimetics | 1 | 2012 | 33 | 0.420 |
Why?
|
| Phosphorylation | 13 | 2017 | 4804 | 0.410 |
Why?
|
| Dinoprostone | 3 | 2011 | 208 | 0.410 |
Why?
|
| Interleukin-4 | 3 | 2017 | 284 | 0.400 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2011 | 84 | 0.400 |
Why?
|
| Inflammatory Breast Neoplasms | 2 | 2017 | 509 | 0.380 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2011 | 200 | 0.370 |
Why?
|
| Fluorenes | 2 | 2009 | 17 | 0.370 |
Why?
|
| Charcoal | 1 | 2009 | 8 | 0.350 |
Why?
|
| Pyrrolidines | 1 | 2009 | 113 | 0.340 |
Why?
|
| Palladium | 1 | 2009 | 56 | 0.330 |
Why?
|
| Dipeptides | 1 | 2009 | 91 | 0.330 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2009 | 146 | 0.330 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2330 | 0.310 |
Why?
|
| Hydrogen | 1 | 2007 | 58 | 0.300 |
Why?
|
| Pyrroles | 1 | 2011 | 576 | 0.300 |
Why?
|
| Cyclic S-Oxides | 1 | 2006 | 12 | 0.300 |
Why?
|
| Amino Acid Sequence | 15 | 2009 | 4233 | 0.290 |
Why?
|
| Glutamic Acid | 1 | 2009 | 309 | 0.290 |
Why?
|
| Threonine | 1 | 2006 | 161 | 0.280 |
Why?
|
| Interleukin-13 | 2 | 2017 | 135 | 0.280 |
Why?
|
| Alkanes | 1 | 2005 | 4 | 0.280 |
Why?
|
| Bridged Bicyclo Compounds | 1 | 2005 | 5 | 0.280 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2005 | 10 | 0.280 |
Why?
|
| Protein Conformation | 9 | 2016 | 1258 | 0.270 |
Why?
|
| Neovascularization, Pathologic | 2 | 2012 | 1547 | 0.260 |
Why?
|
| Magnetic Resonance Spectroscopy | 6 | 2014 | 624 | 0.260 |
Why?
|
| Protein-Tyrosine Kinases | 7 | 2001 | 1756 | 0.260 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 669 | 0.260 |
Why?
|
| Serine | 1 | 2006 | 388 | 0.260 |
Why?
|
| Antineoplastic Agents | 6 | 2013 | 14289 | 0.260 |
Why?
|
| Peptidomimetics | 2 | 2015 | 26 | 0.250 |
Why?
|
| Trans-Activators | 3 | 2009 | 1555 | 0.240 |
Why?
|
| Protein Binding | 10 | 2014 | 3438 | 0.230 |
Why?
|
| Sulfonamides | 3 | 2011 | 1823 | 0.230 |
Why?
|
| Heart Failure | 4 | 2022 | 2516 | 0.220 |
Why?
|
| Inhibitory Concentration 50 | 6 | 2013 | 289 | 0.210 |
Why?
|
| Crystallography, X-Ray | 3 | 2009 | 627 | 0.210 |
Why?
|
| Drug Design | 4 | 2012 | 375 | 0.200 |
Why?
|
| Scleroderma, Systemic | 1 | 2022 | 134 | 0.200 |
Why?
|
| Long Term Adverse Effects | 1 | 2021 | 23 | 0.200 |
Why?
|
| Molecular Sequence Data | 13 | 2009 | 6089 | 0.200 |
Why?
|
| Cell Line, Tumor | 13 | 2017 | 14551 | 0.200 |
Why?
|
| Catalysis | 2 | 2014 | 250 | 0.190 |
Why?
|
| Cell Line | 4 | 2018 | 5114 | 0.190 |
Why?
|
| Hydrogen Bonding | 3 | 2012 | 126 | 0.180 |
Why?
|
| Ligands | 3 | 2013 | 995 | 0.180 |
Why?
|
| Phenylalanine | 1 | 2000 | 142 | 0.180 |
Why?
|
| Macrophages | 2 | 2017 | 1304 | 0.180 |
Why?
|
| Brain Ischemia | 1 | 2022 | 292 | 0.180 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2015 | 243 | 0.180 |
Why?
|
| Receptors, Prostaglandin E | 2 | 2010 | 14 | 0.170 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2021 | 223 | 0.170 |
Why?
|
| Breast Neoplasms | 7 | 2014 | 15694 | 0.170 |
Why?
|
| Transcriptional Activation | 2 | 2015 | 1070 | 0.160 |
Why?
|
| Acrylic Resins | 1 | 1998 | 43 | 0.160 |
Why?
|
| Dimerization | 3 | 2009 | 304 | 0.150 |
Why?
|
| Enzyme Inhibitors | 3 | 2000 | 1879 | 0.150 |
Why?
|
| Animals | 18 | 2018 | 59536 | 0.150 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2017 | 68 | 0.150 |
Why?
|
| Kinetics | 4 | 2011 | 2049 | 0.150 |
Why?
|
| Tyrosine | 2 | 2015 | 498 | 0.150 |
Why?
|
| Antibody Formation | 1 | 1998 | 383 | 0.140 |
Why?
|
| Mice | 12 | 2018 | 34495 | 0.140 |
Why?
|
| Radiation Tolerance | 2 | 2017 | 629 | 0.140 |
Why?
|
| Cell Polarity | 1 | 2017 | 208 | 0.140 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 503 | 0.140 |
Why?
|
| Diuretics | 1 | 2017 | 170 | 0.140 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2015 | 22 | 0.140 |
Why?
|
| Receptors, Interleukin-3 | 1 | 2015 | 26 | 0.140 |
Why?
|
| Fluorescence Polarization | 2 | 2005 | 22 | 0.140 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 2195 | 0.140 |
Why?
|
| Protein Kinase C | 1 | 2017 | 396 | 0.140 |
Why?
|
| Hydrazones | 1 | 2016 | 42 | 0.140 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2015 | 34 | 0.130 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2016 | 222 | 0.130 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 4053 | 0.130 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2015 | 57 | 0.130 |
Why?
|
| Substrate Specificity | 8 | 1999 | 549 | 0.130 |
Why?
|
| Chelating Agents | 1 | 2016 | 127 | 0.130 |
Why?
|
| Zinc | 1 | 2016 | 188 | 0.130 |
Why?
|
| Hydrogenation | 1 | 2014 | 3 | 0.130 |
Why?
|
| Humans | 34 | 2022 | 261506 | 0.130 |
Why?
|
| Stroke | 2 | 2022 | 1144 | 0.130 |
Why?
|
| Protein Structure, Tertiary | 4 | 2011 | 1487 | 0.130 |
Why?
|
| Resins, Plant | 1 | 1994 | 3 | 0.130 |
Why?
|
| src-Family Kinases | 4 | 2003 | 478 | 0.130 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2015 | 106 | 0.130 |
Why?
|
| DNA-Binding Proteins | 3 | 2013 | 4821 | 0.130 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2015 | 212 | 0.120 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2014 | 93 | 0.120 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2015 | 118 | 0.120 |
Why?
|
| Indicators and Reagents | 3 | 2006 | 128 | 0.120 |
Why?
|
| RANK Ligand | 1 | 2014 | 119 | 0.120 |
Why?
|
| Pyrvinium Compounds | 1 | 2013 | 7 | 0.120 |
Why?
|
| Receptors, Adrenergic, beta-2 | 2 | 2015 | 123 | 0.120 |
Why?
|
| Signal Transduction | 8 | 2016 | 11965 | 0.120 |
Why?
|
| Aspergillus fumigatus | 1 | 2014 | 135 | 0.120 |
Why?
|
| Molecular Conformation | 2 | 2013 | 171 | 0.110 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2014 | 203 | 0.110 |
Why?
|
| Caspases | 1 | 2016 | 661 | 0.110 |
Why?
|
| Fungal Proteins | 1 | 2014 | 254 | 0.110 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2003 | 182 | 0.110 |
Why?
|
| Colon | 1 | 2016 | 670 | 0.110 |
Why?
|
| Female | 15 | 2022 | 141928 | 0.100 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2011 | 566 | 0.100 |
Why?
|
| Fibroblasts | 2 | 2016 | 1682 | 0.100 |
Why?
|
| Binding Sites | 5 | 2014 | 2171 | 0.100 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2013 | 363 | 0.100 |
Why?
|
| Stereoisomerism | 2 | 2005 | 164 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2011 | 1678 | 0.100 |
Why?
|
| Adenoma | 1 | 2016 | 716 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 1033 | 0.090 |
Why?
|
| G-Protein-Coupled Receptor Kinase 5 | 1 | 2009 | 8 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 1130 | 0.090 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2011 | 323 | 0.090 |
Why?
|
| G-Protein-Coupled Receptor Kinases | 1 | 2009 | 25 | 0.090 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2016 | 713 | 0.090 |
Why?
|
| Rhodopsin | 1 | 2009 | 70 | 0.090 |
Why?
|
| Lung | 2 | 2018 | 3151 | 0.090 |
Why?
|
| RGS Proteins | 1 | 2009 | 61 | 0.090 |
Why?
|
| Receptors, Notch | 1 | 2013 | 383 | 0.090 |
Why?
|
| Valine | 2 | 2004 | 176 | 0.090 |
Why?
|
| Mice, Nude | 3 | 2013 | 4307 | 0.090 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2009 | 85 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 4938 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2016 | 895 | 0.080 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2008 | 71 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2016 | 8873 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 1390 | 0.080 |
Why?
|
| Organophosphorus Compounds | 2 | 2001 | 101 | 0.080 |
Why?
|
| Molecular Structure | 2 | 2005 | 515 | 0.080 |
Why?
|
| Transcription Factors | 3 | 2014 | 5270 | 0.080 |
Why?
|
| Oxidation-Reduction | 1 | 2009 | 717 | 0.070 |
Why?
|
| Apoptosis | 3 | 2016 | 7591 | 0.070 |
Why?
|
| Piperazines | 1 | 2016 | 2101 | 0.070 |
Why?
|
| Rats | 1 | 2015 | 6086 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2013 | 3821 | 0.070 |
Why?
|
| Fluoroacetates | 1 | 1986 | 9 | 0.070 |
Why?
|
| Trypsin Inhibitors | 1 | 1986 | 18 | 0.070 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 1986 | 25 | 0.070 |
Why?
|
| Trypsin | 1 | 1986 | 140 | 0.070 |
Why?
|
| Pentetic Acid | 1 | 2005 | 48 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 2 | 2012 | 5395 | 0.070 |
Why?
|
| Cytosine Deaminase | 1 | 2005 | 39 | 0.070 |
Why?
|
| Catechols | 2 | 1995 | 14 | 0.070 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2005 | 45 | 0.070 |
Why?
|
| Proteins | 1 | 2013 | 1963 | 0.060 |
Why?
|
| Receptors, Interferon | 1 | 2005 | 44 | 0.060 |
Why?
|
| Mice, Knockout | 4 | 2015 | 5710 | 0.060 |
Why?
|
| Endopeptidases | 1 | 1986 | 220 | 0.060 |
Why?
|
| Amino Acids | 2 | 2001 | 728 | 0.060 |
Why?
|
| Tyrphostins | 2 | 1995 | 107 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 6942 | 0.060 |
Why?
|
| Mutation | 6 | 2016 | 15179 | 0.060 |
Why?
|
| Viruses | 1 | 2005 | 159 | 0.060 |
Why?
|
| Oncogene Protein pp60(v-src) | 2 | 1994 | 17 | 0.060 |
Why?
|
| Blotting, Western | 3 | 2016 | 3536 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2004 | 305 | 0.050 |
Why?
|
| Denmark | 1 | 2021 | 48 | 0.050 |
Why?
|
| Cell Proliferation | 4 | 2016 | 7226 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2016 | 6150 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2005 | 1944 | 0.050 |
Why?
|
| Immunoprecipitation | 2 | 2016 | 591 | 0.050 |
Why?
|
| Nitriles | 2 | 1995 | 906 | 0.050 |
Why?
|
| Phosphates | 1 | 2001 | 187 | 0.050 |
Why?
|
| In Vitro Techniques | 2 | 2003 | 1618 | 0.050 |
Why?
|
| Isoindoles | 2 | 2010 | 11 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2005 | 1694 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2003 | 2488 | 0.040 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 2 | 2010 | 23 | 0.040 |
Why?
|
| Biochemistry | 1 | 1999 | 24 | 0.040 |
Why?
|
| Peptide Fragments | 3 | 2017 | 1271 | 0.040 |
Why?
|
| Esters | 2 | 1999 | 45 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2013 | 1869 | 0.040 |
Why?
|
| Mortality | 1 | 2021 | 343 | 0.040 |
Why?
|
| Resins, Synthetic | 1 | 1998 | 3 | 0.040 |
Why?
|
| Chemokine CCL22 | 1 | 2017 | 13 | 0.040 |
Why?
|
| Molecular Probes | 1 | 1998 | 72 | 0.040 |
Why?
|
| Defibrillators, Implantable | 1 | 2021 | 221 | 0.040 |
Why?
|
| Mannose-Binding Lectins | 1 | 2017 | 29 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2017 | 55 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2009 | 997 | 0.040 |
Why?
|
| Chickens | 1 | 1998 | 523 | 0.040 |
Why?
|
| Solubility | 1 | 1998 | 242 | 0.040 |
Why?
|
| Lipoproteins | 1 | 1999 | 252 | 0.040 |
Why?
|
| Biomimetic Materials | 1 | 2017 | 41 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 2017 | 249 | 0.040 |
Why?
|
| Cross-Linking Reagents | 1 | 1998 | 153 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2016 | 5637 | 0.040 |
Why?
|
| Fibronectins | 1 | 2017 | 197 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2005 | 1616 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 162 | 0.040 |
Why?
|
| Antigens | 1 | 1998 | 292 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2003 | 2927 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 2 | 2010 | 483 | 0.040 |
Why?
|
| Cell Survival | 2 | 2013 | 3045 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2021 | 358 | 0.040 |
Why?
|
| Salmeterol Xinafoate | 1 | 2015 | 22 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2017 | 626 | 0.030 |
Why?
|
| Cattle | 1 | 1998 | 783 | 0.030 |
Why?
|
| Bronchoconstriction | 1 | 2015 | 22 | 0.030 |
Why?
|
| beta-Arrestins | 1 | 2015 | 44 | 0.030 |
Why?
|
| Arrestins | 1 | 2015 | 46 | 0.030 |
Why?
|
| Aspergillus niger | 1 | 2015 | 25 | 0.030 |
Why?
|
| Propanolamines | 1 | 2015 | 44 | 0.030 |
Why?
|
| Gene Expression | 2 | 2015 | 3570 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 2 | 2008 | 156 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2004 | 1054 | 0.030 |
Why?
|
| Formoterol Fumarate | 1 | 2015 | 51 | 0.030 |
Why?
|
| Fluoresceins | 2 | 2005 | 73 | 0.030 |
Why?
|
| Albuterol | 1 | 2015 | 76 | 0.030 |
Why?
|
| Carbazoles | 1 | 2015 | 87 | 0.030 |
Why?
|
| Ovalbumin | 1 | 2015 | 254 | 0.030 |
Why?
|
| Hypotension | 1 | 2017 | 210 | 0.030 |
Why?
|
| Troponin T | 1 | 2017 | 261 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2003 | 1823 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2004 | 1374 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 173 | 0.030 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2014 | 36 | 0.030 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2014 | 37 | 0.030 |
Why?
|
| Carbodiimides | 1 | 1994 | 7 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 3639 | 0.030 |
Why?
|
| Male | 7 | 2022 | 123000 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 974 | 0.030 |
Why?
|
| DNA | 1 | 2003 | 2693 | 0.030 |
Why?
|
| Solvents | 1 | 1994 | 66 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2017 | 343 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2014 | 208 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 1382 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 518 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2014 | 3154 | 0.030 |
Why?
|
| 5' Untranslated Regions | 1 | 2014 | 93 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 862 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2016 | 1165 | 0.030 |
Why?
|
| Polymers | 1 | 1995 | 223 | 0.030 |
Why?
|
| Glioma | 1 | 2005 | 1963 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 1062 | 0.030 |
Why?
|
| Anthelmintics | 1 | 2013 | 69 | 0.030 |
Why?
|
| Transcription Factor HES-1 | 1 | 2013 | 49 | 0.030 |
Why?
|
| Molecular Docking Simulation | 1 | 2013 | 144 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 2170 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2015 | 446 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2013 | 6915 | 0.030 |
Why?
|
| Age Factors | 1 | 2022 | 5377 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2013 | 222 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 2016 | 741 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2014 | 558 | 0.030 |
Why?
|
| Angiotensin II | 1 | 1993 | 198 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2014 | 575 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 1217 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2013 | 286 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 2422 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 2216 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2014 | 461 | 0.030 |
Why?
|
| Melanoma | 2 | 2005 | 5317 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2017 | 2588 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2015 | 943 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2014 | 829 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2017 | 1467 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 2010 | 3981 | 0.020 |
Why?
|
| Prostaglandins E | 1 | 2010 | 23 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 11538 | 0.020 |
Why?
|
| Receptors, Prostaglandin E, EP3 Subtype | 1 | 2010 | 11 | 0.020 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 430 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 905 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 1489 | 0.020 |
Why?
|
| Chromatography, Thin Layer | 2 | 2005 | 70 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2013 | 771 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2014 | 1038 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 1053 | 0.020 |
Why?
|
| Mass Spectrometry | 2 | 2005 | 702 | 0.020 |
Why?
|
| Static Electricity | 1 | 2009 | 58 | 0.020 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2009 | 44 | 0.020 |
Why?
|
| beta Catenin | 1 | 2013 | 688 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2010 | 256 | 0.020 |
Why?
|
| Middle Aged | 4 | 2022 | 86204 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2016 | 3033 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 622 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2009 | 336 | 0.020 |
Why?
|
| Crystallography | 1 | 2008 | 57 | 0.020 |
Why?
|
| Cell Movement | 1 | 2016 | 2466 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 2074 | 0.020 |
Why?
|
| Time Factors | 3 | 2008 | 12926 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2014 | 1549 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 973 | 0.020 |
Why?
|
| Adult | 3 | 2021 | 77950 | 0.020 |
Why?
|
| Protein Kinases | 1 | 1992 | 874 | 0.020 |
Why?
|
| Histones | 1 | 2014 | 1466 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 1143 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6207 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 14889 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 2864 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 2291 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 3101 | 0.020 |
Why?
|
| Chemistry | 1 | 1986 | 99 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1986 | 137 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1493 | 0.020 |
Why?
|
| Software | 1 | 2013 | 1321 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 6295 | 0.020 |
Why?
|
| Ketones | 1 | 1986 | 54 | 0.020 |
Why?
|
| Titrimetry | 1 | 2005 | 10 | 0.020 |
Why?
|
| Vitronectin | 1 | 2005 | 22 | 0.020 |
Why?
|
| Ultracentrifugation | 1 | 2005 | 46 | 0.020 |
Why?
|
| Risk Factors | 1 | 2022 | 17523 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 5047 | 0.020 |
Why?
|
| Flucytosine | 1 | 2005 | 30 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 1443 | 0.020 |
Why?
|
| Crystallization | 1 | 2005 | 132 | 0.020 |
Why?
|
| Captopril | 1 | 2004 | 34 | 0.020 |
Why?
|
| Life Tables | 1 | 2004 | 120 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 6682 | 0.020 |
Why?
|
| Valsartan | 1 | 2004 | 38 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 1986 | 275 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 392 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2015 | 4078 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1999 | 548 | 0.020 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2005 | 163 | 0.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2004 | 68 | 0.020 |
Why?
|
| Integrins | 1 | 2005 | 262 | 0.010 |
Why?
|
| Tetrazoles | 1 | 2004 | 106 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2009 | 1529 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 611 | 0.010 |
Why?
|
| Aged | 3 | 2017 | 70117 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2003 | 54 | 0.010 |
Why?
|
| Transfection | 2 | 2003 | 2944 | 0.010 |
Why?
|
| Medical Records | 1 | 2004 | 415 | 0.010 |
Why?
|
| COS Cells | 1 | 2003 | 377 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 543 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2004 | 257 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 1082 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 7222 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 1399 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2005 | 1008 | 0.010 |
Why?
|
| Algorithms | 1 | 2013 | 3890 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 1519 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 2005 | 671 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2005 | 621 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2004 | 435 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 13658 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 3552 | 0.010 |
Why?
|
| Inflammation | 1 | 2010 | 2522 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 1972 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2003 | 1764 | 0.010 |
Why?
|
| Acylation | 1 | 1999 | 25 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2005 | 1459 | 0.010 |
Why?
|
| Societies, Scientific | 1 | 1999 | 74 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 2315 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 3254 | 0.010 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 1999 | 153 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 1999 | 208 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 4917 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2003 | 986 | 0.010 |
Why?
|
| Comorbidity | 1 | 2004 | 2352 | 0.010 |
Why?
|
| Prognosis | 1 | 2016 | 21713 | 0.010 |
Why?
|
| Laboratories | 1 | 1999 | 145 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2003 | 1265 | 0.010 |
Why?
|
| Infant | 1 | 2013 | 13310 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 29902 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 10331 | 0.010 |
Why?
|
| Data Collection | 1 | 1999 | 620 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2004 | 2594 | 0.010 |
Why?
|
| Sequence Analysis | 1 | 1996 | 73 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2003 | 2054 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 4988 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 1995 | 149 | 0.010 |
Why?
|
| Drug Stability | 1 | 1994 | 105 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 7548 | 0.010 |
Why?
|
| Manganese | 1 | 1994 | 80 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 1555 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1994 | 585 | 0.010 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1992 | 44 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1992 | 82 | 0.010 |
Why?
|
| Autoradiography | 1 | 1992 | 132 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 31252 | 0.010 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 1992 | 28 | 0.010 |
Why?
|
| Insecta | 1 | 1992 | 76 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 9244 | 0.010 |
Why?
|
| Child | 1 | 2013 | 29154 | 0.010 |
Why?
|
| Cell Division | 1 | 1995 | 2489 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 1992 | 571 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 1994 | 2295 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2004 | 32848 | 0.000 |
Why?
|